Experimental medicine helps patients lose almost a quarter of body weight in early tests

It was shown that an experimental medicine for weight loss helps people lose almost 25% of their body weight in 1A/2B tests at an early stage.

The drug, amicretin, developed by Novo Nordisk, works by replicating two hunger, amiline hormones, which regulates appetite and creates a feeling of fullness, and the peptide similar to glucagon 1 (LPG-1), the same hormone used in Ozempic and Wogovy to suppress appetite and secretion of insulin.

“Amicretin is the first treatment to take advantage of the two different biological pathways stimulated by Amylin and LPG-1 in a single molecule,” said Martin Holst Lange, executive vice president and head of development of Novo Nordisk, previously in a statement sent to News Digital.

Grandfather’s simple changes reversed the diagnosis of pre-diabetes that left him “petrified”

In the study, which included 125 adults overweight or obesity, participants who received weekly amicretin injections lost more weight than those who took a placebo, according to a press release from Novo Nordisk.

Those who obtained the highest doses (up to 60 mg) lost up to 24.3% pounds after 36 weeks, compared to only 1.1% for the placebo group, according to the launch.

A previous phase 1 trial of the oral version (pill) of amicretin also showed that the treatment was “safe and tolerable”, with a “reduction observed in body weight” compared to the placebo, the company said.

Taking the pill once a day led to a weight loss of around 10%, and those who doubled the dose lost 13%.

Your DNA could prevent weight losing, suggests a new study

Another benefit that the researchers stressed is that people who take amicretin did not seem to reach a “weight loss plateau”, which continue to spill pounds while taking it.

“The lack of weight loss plateau indicates the possibility of achieving greater weight reductions with extended treatment,” wrote Agnes Ganoirek, senior specialist of clinical pharmacology in Novo Nordisk, in the findings of the study of phase 1.

Novo Nordisk presented the last findings at the American Diabetes Association in Chicago on June 22; They were also published in the medical magazine Lancet.

“We are satisfied with the promising results of amicretin and the comments of the regulatory authorities and we are excited to advance both the subcutaneous and oral versions of this molecule in the development of phase 3 for weight control,” said Martin Holst Lange, executive vice president of Development of Novo Nordisk, in the launch.

“Amicretin is the first treatment to take advantage of the two different biological pathways stimulated by amiline and LPG-1 in a single molecule.”

“These results reflect our solid pipe in obesity, [and] Our approach in progressing scientific innovation and expanding the range of options available for patients and health professionals. “

The most common side effects of amicretin, similar to other LPG-1, were gastrointestinal symptoms, mainly nausea, vomiting and decreased appetite.

Click here to get the News application

According to researchers, adverse events were “mild to moderate.” The most frequent doses resulted in greater side effects.

It is important to monitor these side effects closely, experts advise, since gastrointestinal problems are common among patients with obesity.

“While the initial weight loss results are really encouraging, more studies are needed to ensure that the therapeutic benefits constantly exceed potential risks, especially with long-term administration,” said Dr. Christine Ren-Fielding, director and head of bariatric surgery in the Nyu Langone weight management program previously, said News Digital.

Click here to register in our health newsletter

Although GLP-1 medicines, including this new experimental pill, can show promising results, the reindeer field, which did not participate in the study, emphasized that “they are not a cure for obesity.”

“Obesity is a chronic and multifactorial disease that requires a long -term integral approach,” he said at that time.

For more health articles, visit www.Newsnews.com/health

“Pharmacological treatments can play an important role in handling the condition, but they are often more effective when combined with other interventions.”

Next, Novo Nordisk plans to prepare for phase 3 tests of the medication, both in oral and injectable forms, for obesity management.